Expertise in
5
conditions

Dr. Rebecca Moroose

Internal Medicine
Florida Home Health Equipment And Supplies Inc
22 Underwood St Fl 3, 
Orlando, FL 
Expertise in
5
conditions
Florida Home Health Equipment And Supplies Inc
22 Underwood St Fl 3, 
Orlando, FL 

Overview

Rebecca Moroose is an Internal Medicine provider in Orlando, Florida. Dr. Moroose is highly rated in 5 conditions, according to our data. Her top areas of expertise are Breast Cancer, Angiosarcoma, Paget Disease of the Breast, and Ovarian Carcinosarcoma.

Her clinical research consists of co-authoring 15 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Internal Medicine

Licenses

Internal Medicine in FL

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Cigna
  • EPO
  • HMO
  • PPO

Locations

Florida Home Health Equipment and Supplies Inc
22 Underwood St Fl 3, Orlando, FL 32806

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

Molecular Analysis for Therapy Choice (MATCH)
Molecular Analysis for Therapy Choice (MATCH)
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Procedure, Drug, Other, Biological
Study Drugs: Adavosertib, Afatinib, Binimetinib, Capivasertib, Copanlisib, Crizotinib, Dabrafenib, Dasatinib, Defactinib, Erdafitinib, FGFR Inhibitor AZD4547, Ipatasertib, Larotrectinib, Nivolumab, Osimertinib, Palbociclib, Pertuzumab, PI3K-Beta Inhibitor GSK2636771, Sapanisertib, Sunitinib, Taselisib, Trametinib, Trastuzumab, Ulixertinib, Vismodegib
Study Phase: Phase 2
A Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy for Metastatic HER2+ Breast Cancer (HER2CLIMB-05)
A Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy for Metastatic HER2+ Breast Cancer (HER2CLIMB-05)
Enrollment Status: Active_not_recruiting
Publish Date: December 04, 2025
Intervention Type: Drug
Study Drugs: Tucatinib, Trastuzumab, Pertuzumab
Study Phase: Phase 3
Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib vs Placebo in Combination With Capecitabine and Trastuzumab in Patients With Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma
Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib vs Placebo in Combination With Capecitabine and Trastuzumab in Patients With Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma
Enrollment Status: Completed
Publish Date: August 14, 2023
Intervention Type: Drug
Study Drugs: tucatinib, capecitabine, trastuzumab
Study Phase: Phase 2
An International, Multi-Center, Open-Label, Randomized, Phase III Trial of Sacituzumab Govitecan Versus Treatment of Physician Choice in Patients With Metastatic Triple-Negative Breast Cancer Who Received at Least Two Prior Treatments
An International, Multi-Center, Open-Label, Randomized, Phase III Trial of Sacituzumab Govitecan Versus Treatment of Physician Choice in Patients With Metastatic Triple-Negative Breast Cancer Who Received at Least Two Prior Treatments
Enrollment Status: Completed
Publish Date: June 15, 2022
Intervention Type: Drug
Study Phase: Phase 3
A Phase I/II Study of IMMU-132 (hRS7-SN38 Antibody Drug Conjugate) in Patients With Epithelial Cancer
A Phase I/II Study of IMMU-132 (hRS7-SN38 Antibody Drug Conjugate) in Patients With Epithelial Cancer
Enrollment Status: Completed
Publish Date: August 12, 2021
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase I/II, Single Arm, Open-label Study of Ribociclib in Combination With Everolimus + Exemestane in the Treatment of Men and Postmenopausal Women With HR+, HER2- Locally Advanced or Metastatic Breast Cancer Following Progression on a CDK 4/6 Inhibitor
A Phase I/II, Single Arm, Open-label Study of Ribociclib in Combination With Everolimus + Exemestane in the Treatment of Men and Postmenopausal Women With HR+, HER2- Locally Advanced or Metastatic Breast Cancer Following Progression on a CDK 4/6 Inhibitor
Enrollment Status: Completed
Publish Date: May 05, 2021
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
An Open-Label, Multi-Center Expanded Access Program of Abemaciclib for the Treatment of Hormone Receptor Positive, HER2 Negative Advanced or Metastatic Breast Cancer in Patients With Disease Progression on Prior Therapies
An Open-Label, Multi-Center Expanded Access Program of Abemaciclib for the Treatment of Hormone Receptor Positive, HER2 Negative Advanced or Metastatic Breast Cancer in Patients With Disease Progression on Prior Therapies
Enrollment Status: Approved_for_marketing
Publish Date: October 31, 2017
Intervention Type: Drug
View 6 Less Clinical Trials

15 Total Publications

Ribociclib Plus Endocrine Therapy in Hormone Receptor-Positive/ERBB2-Negative Early Breast Cancer: 4-Year Outcomes From the NATALEE Randomized Clinical Trial.
Ribociclib Plus Endocrine Therapy in Hormone Receptor-Positive/ERBB2-Negative Early Breast Cancer: 4-Year Outcomes From the NATALEE Randomized Clinical Trial.
Journal: JAMA oncology
Published: September 25, 2025
Similar Doctors
Expertise in
8
conditions
Dr. Richard Pratley
Internal Medicine
Expertise in
8
conditions
Dr. Richard Pratley
Internal Medicine

Office

2415 N Orange Ave Ste 502, 
Orlando, FL 
 (3.8 miles away)
407-303-2801
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Richard Pratley is an Internal Medicine provider in Orlando, Florida. Dr. Pratley is highly rated in 8 conditions, according to our data. His top areas of expertise are Type 2 Diabetes (T2D), Low Blood Sugar, Type 1 Diabetes (T1D), and Maturity Onset Diabetes of the Young.

Expertise in
33
conditions
Dr. Wasim Ahmar
Internal Medicine | Cardiology | Interventional Cardiology
Expertise in
33
conditions
Dr. Wasim Ahmar
Internal Medicine | Cardiology | Interventional Cardiology

Longwood Cardiology

7148 Curry Ford Rd Ste 400, 
Orlando, FL 
 (5.9 miles away)
407-730-7850
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Wasim Ahmar is a Cardiologist and an Internal Medicine provider in Orlando, Florida. Dr. Ahmar is highly rated in 33 conditions, according to our data. His top areas of expertise are Stable Angina, Metabolic Syndrome, Fainting, and Angina. Dr. Ahmar is currently accepting new patients.

Expertise in
52
conditions
Dr. Amish M. Parikh
Internal Medicine | Cardiology
Expertise in
52
conditions
Dr. Amish M. Parikh
Internal Medicine | Cardiology

Premier Cardiology & Vascular Associates LLC

541 E Horatio Ave Ste 100, 
Maitland, FL 
 (7.2 miles away)
407-622-0793
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Amish Parikh is a Cardiologist and an Internal Medicine provider in Maitland, Florida. Dr. Parikh is highly rated in 52 conditions, according to our data. His top areas of expertise are Dilated Cardiomyopathy (DCM), Hypertensive Heart Disease, Pediatric Myocarditis, and Necrosis. Dr. Parikh is currently accepting new patients.

Frequently Asked Questions about Dr. Rebecca Moroose

How do I make an appointment with Dr. Rebecca Moroose?

You can book an appointment with Dr. Rebecca Moroose by calling their office at 407-648-3800. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Rebecca Moroose a top-rated expert for Breast Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Rebecca Moroose is classified as an Distinguished expert for Breast Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Rebecca Moroose specialize in?

While Dr. Rebecca Moroose is a Internal Medicine, they have specific expertise in Breast Cancer, Angiosarcoma, and Paget Disease of the Breast. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Internal Medicine.

Does Dr. Rebecca Moroose participate in research or clinical trials?

Yes. Dr. Rebecca Moroose has published 15 articles and abstracts on conditions like Breast Cancer. You can view a list of Dr. Rebecca Moroose's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Rebecca Moroose accept my insurance?

Dr. Rebecca Moroose accepts most major insurance plans, including Cigna. We recommend calling the office directly at 407-648-3800 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Moroose's expertise for a condition
ConditionClose
    View All 12 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile